Semaglutide Deep-Dive
Also known as: GLP-1 Receptor Agonist · Ozempic (brand) · Wegovy (brand) · Rybelsus (oral brand)
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. Researchers investigate its glucose-dependent insulin secretion potentiation, glucagon suppression, slowed gastric emptying, and central appetite-modulation effects. The compound's structural modifications — including a fatty-acid side chain enabling albumin binding — extend half-life dramatically over native GLP-1 (which has a ~2-minute half-life).
Plasma Half-Life
~7 days
Logarithmic scale · 7 d mapped
Tissue Residency
Sustained receptor exposure throughout weekly dosing interval
Quick Facts
- Typical dose
- 0.25 mg → 2.4 mg weekly (titrated)
- Range
- 0.25 mg starter → 2.4 mg maintenance; some research protocols extend to 3.0 mg
- Route
- Subcutaneous injection, once weekly. Standard titration: 0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg → 1.7 mg → 2.4 mg, escalating monthly to mitigate GI side effects.
- Cycle pattern
- Continuous weekly administration is the standard protocol. Cycling off is discussed in research contexts for tolerance management; rapid cessation is associated with rebound appetite signaling.
- Primary evidence tier
- Clinical
Mechanism of Action
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. Researchers investigate its glucose-dependent insulin secretion potentiation, glucagon suppression, slowed gastric emptying, and central appetite-modulation effects. The compound's structural modifications — including a fatty-acid side chain enabling albumin binding — extend half-life dramatically over native GLP-1 (which has a ~2-minute half-life).
Researchers investigate Semaglutide in the broader context of the Metaboliccompound class. The compound's proposed relationship to underlying physiology is typically framed against the Insulin Resistance axis — a framework DoseCraft uses to organize research priorities across the 90+ compound library.
In the practitioner corpus that trains the DoseCraft AI copilot, Semaglutide's mechanism is repeatedly cross-referenced against its pharmacokinetic profile (plasma half-life ~7 days) because dosing cadence, stack selection, and cycling structure all derive from the PK window. This is the core difference between a static calculator and a PK-aware reasoning layer.
Pharmacokinetics
Plasma Half-Life (Logarithmic)
~7 days
Logarithmic scale · 7 d mapped
Tissue Residency
Sustained receptor exposure throughout weekly dosing interval
Semaglutide has a plasma half-life of approximately ~7 days. This window is the primary driver of every downstream protocol decision: dosing frequency, stack overlap, cycling length, and the observable duration of subjective response.
Beyond the plasma window, sustained receptor exposure throughout weekly dosing interval. This tissue-residency or functional-duration behavior is why practitioner protocols often deviate from what raw plasma half-life alone would suggest.
In the DoseCraft PK model, this compound is mapped onto the same decay-curve framework that powers the half-life visualizer in the app — every stack built in the Protocol Builder factors in the half-life overlap of Semaglutidealongside any co-administered compounds. Static calculators elsewhere ignore this; it's why the practitioner corpus consistently flags half-life literacy as a top-three safety variable.
From real clinicians · not PubMed abstracts
Practitioner Protocols
Practitioner Corpus
Sourced from clinician-validated protocols, bloodwork reviews, and cycle audits. Not PubMed. Not Reddit.
Clinicians who run high-volume metabolic-research practices report Semaglutide as the most-prescribed GLP-1 agonist in the United States, with the standardized monthly titration ladder near-universally followed to mitigate the dose-dependent GI side effects (nausea, constipation, occasional vomiting) that drive the majority of early discontinuations. In protocol audits we've reviewed, practitioners increasingly pair Semaglutide with BPC-157 for gut-tolerance research and emphasize that rapid titration without the 4-week interval produces predictable tolerability failures. Tirzepatide is the dominant comparator and the dual-agonism profile is considered structurally superior in current practitioner consensus.
Dosing
0.25 mg → 2.4 mg weekly (titrated)
Subcutaneous injection, once weekly. Standard titration: 0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg → 1.7 mg → 2.4 mg, escalating monthly to mitigate GI side effects.
Cycle
Continuous weekly administration is the standard protocol. Cycling off is discussed in research contexts for tolerance management; rapid cessation is associated with rebound appetite signaling.
Evidence Breakdown
Every finding about Semaglutideis categorized across three independent evidence lanes. You always know what research tier you’re acting on.
- Strongest clinical evidence base on this list — multiple Phase III trials (STEP, SUSTAIN, PIONEER programs) and FDA approvals for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).
- Universal practitioner consensus on titration ladder and GI-tolerance management. Most-prescribed GLP-1 in active practice.
- Emerging research investigates cardiovascular outcome benefits, NAFLD applications, and addiction-modulation effects independent of weight reduction.
Cycling & Stack Considerations
Cycling Protocol
Continuous weekly administration is the standard protocol. Cycling off is discussed in research contexts for tolerance management; rapid cessation is associated with rebound appetite signaling.
Common Stacks
- •Semaglutide solo (the dominant protocol)
- •Semaglutide + BPC-157 (gut-tolerance research stack)
- •Semaglutide + CJC-1295/Ipamorelin (body-composition research stack)
Interactions & Overlap
- •Tirzepatide (mechanistically overlapping; not co-administered)
- •Insulin and sulfonylureas (hypoglycemia risk; dose adjustment required in research contexts)
- •Oral medications (slowed gastric emptying may affect absorption — particularly oral contraceptives, levothyroxine)
Honest negatives · the part other trackers skip
Contraindications & Watch-Outs
Research Watch-Outs
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis (relative contraindication; practitioner judgment)
- Pregnancy and lactation — animal studies indicate fetal harm
- Severe gastroparesis or active GI motility disorders
Semaglutide FAQs
What is the half-life of Semaglutide?
Semaglutide has an approximate 7-day plasma half-life — produced by structural modifications (including a fatty-acid side chain enabling serum-albumin binding). This long half-life is why dosing is once weekly.
What is the typical Semaglutide titration schedule?
Standard titration: 0.25 mg weekly × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg × 4 weeks → 1.7 mg × 4 weeks → 2.4 mg maintenance. The monthly intervals are designed to mitigate dose-dependent GI side effects.
Semaglutide vs Tirzepatide — which is better?
Tirzepatide is a dual GIP/GLP-1 agonist; Semaglutide is GLP-1-only. Head-to-head clinical trial data (SURMOUNT vs STEP) suggests Tirzepatide produces greater research outcomes on metabolic endpoints. Practitioner consensus increasingly favors Tirzepatide where supply permits.
What are the side effects of Semaglutide?
Most-reported: nausea, constipation, vomiting, abdominal discomfort — predominantly during titration. Serious considerations include pancreatitis risk and the boxed warning regarding medullary thyroid carcinoma in animal models.
Can Semaglutide be cycled off?
Continuous weekly administration is the standard protocol. Discontinuation is associated with rebound appetite signaling and weight regain in clinical studies. Cycling is discussed in research contexts but is not the dominant protocol.
Does Semaglutide cause muscle loss?
Loss of lean body mass during caloric deficit is a documented research finding, not unique to Semaglutide but to any sustained caloric reduction. Practitioner protocols increasingly pair Semaglutide research with resistance training and protein-intake monitoring.
How long until Semaglutide produces results?
In clinical research, measurable changes appear within 4–8 weeks of titration onset. Maximal research effects typically appear at 6–12 months on maintenance dose.
Related Compounds
Track your Semaglutide protocol in DoseCraft
The PK-aware protocol builder models ~7 days decay, checks stack overlap, and flags contraindications — built on the same practitioner corpus that powers this page.
See pricingFor research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Content on this page is educational and does not constitute medical advice, dosing guidance, or a protocol recommendation. Consult a qualified clinician before undertaking any research involving peptide compounds.